Online Program

280943
A randomized controlled trial of tailored navigation and standard intervention in colorectal cancer screening


Wednesday, November 6, 2013 : 10:45 a.m. - 11:00 a.m.

Ronald E. Myers, PhD, Department of Medical Oncology, Division of Population Science, Thomas Jefferson University, Philadelphia, PA
Heather Bittner-Fagan, MD, FAAFP, MPH, Christiana Care Health System, Wilmington, DE
Constantine Daskalakis, ScD, Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
Randa Sifri, MD, Department of Family & Community Medicine, Thomas Jefferson University, Philadelphia, PA
Sally W. Vernon, PhD, Center for Health Promotion and Prevention Research, University of Texas-Houston School of Public Health, Houston, TX
James Cocroft, MA, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA
Melissa DiCarlo, MPH, MS, Department of Medical Oncology, Division of Population Science, Thomas Jefferson University, Philadelphia, PA
Nora Katurakes, RN, MSN, OCN, Christiana Care Health System, Wilmington, DE
Jocelyn Andrel, MSPH, Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
Background. This randomized, controlled trial assessed the impact of a tailored navigation intervention versus a standard mailed intervention on colorectal cancer (CRC) screening adherence and screening decision stage (SDS). Methods. Primary care patients (n=945) were surveyed and randomized to a Tailored Navigation Intervention (TNI) Group (n=312), Standard Intervention (SI) Group (n=316), or usual care Control Group (n=317). TNI Group participants were sent colonoscopy instructions and/or stool blood tests according to reported test preference, and received a navigation call. The SI Group was sent both colonoscopy instructions and stool blood tests. Multivariable analyses assessed intervention impact on adherence and change in SDS at 6 months. Results. The primary outcome, screening adherence (TNI Group: 38%, SI Group: 33%, Control Group: 12%), was higher for intervention recipients than controls (p=0.001 and p=0.001, respectively), but the two intervention groups did not differ significantly (p=0.201). Positive SDS change (TNI Group: +45%, SI Group: +37%, and Control Group: +23%) was significantly greater among intervention recipients than controls (p=0.001 and p=0.001, respectively), and the intervention group difference approached significance (p=0.053). Secondary analyses indicate that tailored navigation boosted preferred test use, and suggest that intervention impact on adherence and SDS was attenuated by limited access to screening options. Conclusions. Both interventions had significant, positive effects on outcomes compared to usual care. TNI versus SI impact had a modest positive impact on adherence and a pronounced effect on SDS. Impact. Mailed screening tests can boost adherence. Research should determine differential effects of preference, access, and navigation on screening outcomes.

Learning Areas:

Chronic disease management and prevention
Communication and informatics
Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs
Public health or related education
Social and behavioral sciences

Learning Objectives:
Explain how to assess colorectal cancer screening test preference Describe a preference-based access and navigation screening inervention, and a standard mailed screening intervention. Compare the effects of a preference-based access and navigation intervention versus a standard mailed access intervention versus usual care on screening adherence

Keyword(s): Cancer Screening, Health Care Delivery

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: As principal investigator of the research project, I led the design, implementation, and evaluation of the study.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.